Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TSC 204

Next Previous
X
Search
Drug Profile

TSC 204

Alternative Names: TSC-204; TSC-204-A0201; TSC-204-C07; TSC-204-C0702

Latest Information Update: 19 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TScan Therapeutics
  • Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Anal cancer; Cervical cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer

Most Recent Events

  • 06 Mar 2024 Tscan Therapeutics plans a phase I trial for Solid tumours in the first quarter of 2024
  • 06 Mar 2024 US FDA approves IND application for TSC 204 for TSC-204-A0101 in Solid tumours
  • 31 Dec 2023 TScan Therapeutics files an IND application with the US FDA for MAGE-A1 (A0101) targeting Ovarian cancer, Non-small cell lung cancer, Malignant melanoma, Macroglobulinaemia, Head and neck cancer and Anal cancer

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top